At-home Dosing Adherence During Characterized Oral Desensitization Immunotherapy (CODIT) for Peanut Allergy

Overview of attention for article published in The Journal of Allergy and Clinical Immunology, February 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news: 8 news outlets

Readers on

mendeley: 3 Mendeley

So far, Altmetric has seen 9 news stories from 8 outlets.

Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma

BioMed Reports, 27 Feb 2017

Feb. 27, 2017 13:00 UTC BRISBANE, Calif.--( BUSINESS WIRE )-- Aimmune Therapeutics, Inc.

Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of …

Yahoo! Finance USA, 27 Feb 2017

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing CODIT™ (Characterize…

Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma

Ariva, 27 Feb 2017

BRISBANE, Calif. --(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Cha…

Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma

Wall Street Online Denmark, 27 Feb 2017

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 5 additional news stories.